Gyre Therapeutics (GYRE) Assets (2010 - 2026)

Gyre Therapeutics (GYRE) has 17 years of Assets data on file, last reported at $162.0 million in Q1 2026.

• Assets for Q1 2026 came in at $162.0 million, up 24.83% year-over-year; the trailing twelve-month figure through Mar 2026 was $162.0 million (up 24.83% YoY), and the FY2025 annual result was $166.1 million, up 32.48% from the prior year.
• Assets fell to $162.0 million in Q1 2026 per GYRE's latest filing, from $166.1 million in the prior quarter.
• Over five years, Assets peaked at $166.1 million in Q4 2025 and troughed at $10.0 million in Q3 2023.
• A 5-year average of $97.7 million and a median of $120.9 million in 2024 frame the typical range for Assets.
• The sharpest annual moves came in 2023 and 2024: Assets tumbled 85.13% in 2023, then surged 1156.92% in 2024.
• A 5-year view of Assets shows it stood at $84.8 million in 2022, then jumped by 37.5% to $116.5 million in 2023, then advanced by 7.61% to $125.4 million in 2024, then soared by 32.48% to $166.1 million in 2025, then declined by 2.48% to $162.0 million in 2026.
• Business Quant data shows GYRE's Assets at $162.0 million in Q1 2026, $166.1 million in Q4 2025, and $159.4 million in Q3 2025.